Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose dementia has been rated between 0.5 and 2 on a standard clinical scale used to measure dementia severity
- People who have been diagnosed with early Alzheimer's disease, mild dementia, or mild cognitive impairment (MCI) and who also have long-term pain (not caused by cancer) that has lasted more than 3 months, happens most days, and gets in the way of daily life or work — or caregivers of someone with that diagnosis and pain condition
- People who are able to give their own informed consent to take part in the study
- People who are willing to wear a brainwave-monitoring headset and a heart rate monitor during the study
- People who are willing to answer survey questions related to the study topics
- People who are willing to have audio and/or video recordings made during the study
- People who are willing to take part in sensory testing, a blood draw, heart rate monitoring, and thinking and memory tests
Who may not be able to join:
- People whose dementia rating falls below 0.5 or above 2 on the standard clinical scale
- People who are not able to give their own informed consent to participate
- People who are currently having thoughts of suicide, self-harm, or harming others above a level defined in the study's safety plan
- People who are already taking part in another clinical trial focused on Alzheimer's disease or dementia
- People who have started a new prescription medication within the last 4 weeks
- People who are taking medications that act on the brain or nervous system and that may affect the study's measurements, as determined by the lead researcher (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: AZA Allsop, MD, PhD, Yale University
Phone: 240-422-3289
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in pain phenotyping using a Quantitative Sensory Testing (QST); Change in pain central sensitization; Change in cortisol levels; Change in oxytocin levels
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.